leadf
logo-loader
viewHumanigen, Inc.
(
NASDAQ:HGEN
)

Full interview: Humanigen plans Phase III clinical trial for lenzilumab to treat symptoms of coronavirus patients

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive the firm wants to carry out a Phase III clinical trial for its lenzilumab to treat cytokine storm, which can lead to acute respiratory distress syndrome (ARDS), which is associated with the current coronavirus pandemic.

Durrant says additionally, lenzilumab is available for physicians who request it through compassionate use immediately.

Quick facts: Humanigen, Inc.

Follow
NASDAQ:HGEN

Price: 6.36 USD

Market Cap: $377.83 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Delta 9 Cannabis hit top 10 of Globe and Mail's Top Growth companies survey

Delta 9 Cannabis CEO John Arbuthnot joined Steve Darling from Proactive to share news the company finished 7th in the Globe and Mail’s 3rd Annual Top Company growth survey with 448 entrants based on 3-year growth. Delta 9 saw an increase of revenue over 3 years of 5,413 percent. Arbuthnot...

2 hours, 6 minutes ago

2 min read